{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
NCT02190279: Early Phase 1 Interventional Completed Prostatic Neoplasms
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor-associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. F 18 DCFBC is investigated in phase 2 clinical trials in patients with prostate cancer.
Status:
Investigational
Source:
NCT01927666: Not Applicable Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01408667: Phase 1/Phase 2 Interventional Completed Metabolic Cardiovascular Syndrome
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
TRC-150094 is a synthetic compound that displays the capacity to stimulate energy expenditure. TRC-150094 increases whole body energy expenditure, increases mitochondrial fatty acid oxidation (FAO), and reduces abdominal adiposity in rats fed a high-fat diet. TRC-150094 attenuates the progression of hypertension, insulin resistance, dysglycemia, and atherogenic dyslipidemia, factors reported to signify significant cardiovascular (CV) risk amongst viscerally obese dysglycemic subjects. Moreover, at organ level, TRC150094 reduced steatohepatitis, reduced progression of nephropathy, and preserved cardiac contractile function. Pharmacological profile of TRC-150094 may constitute a promising new class of molecules that may have a potential beneficial therapeutic approach for the treatment of nontraditional CV risk factors and may reduce residual risk in viscerally obese dysglycemic patients. Moreover, the observed metabolic and functional effects on skeletal muscle suggest that TRC-150094 as a therapy may help to facilitate adherence to prescribed exercise, which would remain the mainstay along with diet control in such patients. Simultaneous systemic administration of TRC-150094 to rats receiving an high-fat diet results in a reduction in fat accumulation within the liver and a marked reduction in adipose tissue mass. TRC-150094 is in phase-III clinical trials for the treatment of diabetes mellitus, hypertension and dyslipidaemias (adjunctive treatment) in India.
Status:
Investigational
Source:
NCT03078322: Phase 2 Interventional Completed Major Depressive Disorder
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
4‐Chlorokynurenine (AV-101) is a neuropharmaceutical drug candidate in development for the treatment of major depressive disorder. Pharmacology studies conducted in rodent models have demonstrated AV-101’s antihyperalgesic activity in models of facilitated
pain processing was seen at serum concentrations ranging from
150–300 M. In addition, AV-101 has been shown to be
neuroprotective activity against an intrahippocampal injection of
quinolinic acid, reductions in seizures, and antidepressive activity. An oral prodrug, AV-101, which, in the brain, is converted into one of the most potent and selective GlyB site antagonists of the NMDAR, has been demonstrated to be active in animal models of neuropathic pain. The two Phase 1 studies were designed to assess the safety and pharmacokinetics of AV-101, over a wide dose range, after daily dosing for 14-days. AV-101 has excellent safety and PK characteristics providing support for advancing AV-101 into Phase 2 studies in neuropathic pain.
Status:
Investigational
Source:
NCT04234100: Not Applicable Interventional Completed Blood Pressure
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01701089: Phase 1 Interventional Completed Healthy Volunteer, Alzheimer's Disease
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
L-DEPRENYL-D2 C-11 is a selective irreversible inhibitor of monoamine oxidase B (Mao-B) which labels functionally active enzyme. It is used as a positron emission tomography radioligand for measurement of the Mao-B activity in vivo brain.
Status:
Investigational
Source:
NCT00005835: Phase 1 Interventional Completed Neuroblastoma
(2001)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Buthionine sulfoximine (BSO) is a selective inhibitor of γ-glutamylcysteine synthetase (γ-GCS), the rate-limiting enzyme in glutathione (GSH) synthesis. In cancer cells, glutathione depletion significantly increased cytotoxicity via oxidative stress. In addition, in neuroblastoma cells susceptible to Buthionine sulfoximine treatment, DNA damage and cell apoptosis occurred via ROS production. Buthionine sulfoximine plus melphalan was effective in treatment for patients with recurrent/refractory neuroblastoma. Buthionine sulfoximine may also be used to increase the sensitivity of parasites to oxidative antiparasitic drugs. Buthionine sulfoximine has been shown to increase the efficacy of nifurtimox against T. cruzi and has also been shown to be an effective modulator of GSH-mediated chemoresistance by increasing the in vitro cytotoxicity of alkylating agents and radiation. Buthionine sulfoximine has been tested in animal studies and in human phase I trials for adults with solid tumors, with documented clinical responses in patients with melanoma, ovarian carcinoma and small cell carcinoma of the lung treated with the combination of Buthionine sulfoximine and melphalan.
Status:
Investigational
Source:
USAN:CALCIUM CHLORIDE CA 45 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Calcium Cation Ca-45 is a calcium radioactive isotope which used for evaluation of calcium absorption and intracellular concentration in scientific research. There are several calcium radionuclides available, including 41Ca, 45Ca, and 47Ca. For practical reasons, 45Ca is the most commonly used calcium radionuclide for biological investigations.
Status:
Investigational
Source:
USAN:CALCIUM CHLORIDE CA 47 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Calcium Cation Ca-47 is a rare calcium radioactive isotope which used in orthopaedics for bone formation evaluation. Calcium-47 has a half-life of about five days, which is long enough for numerous biological investigations and short enough to ensure that the person subjected to the investigation is not under prolonged irradiation. It emits gamma rays in addition to beta rays, and since the gamma rays are capable of penetrating many centimeters of tissue, determination of calcium-47 in the body is possible by external measurements. Unfortunately, calcium-47 is difficult to produce and did not use in routine medical practice
Status:
Investigational
Source:
NCT03516448: Phase 3 Interventional Unknown status Hepatocellular Carcinoma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tyroserleutide (YSL) is a tripeptide treatment being developed by Shenzhen Kangzhe Pharmaceutical Co Ltd, a subsidary of China Medical System Holdings (CMS), for the treatment of liver cancer. It is initially separated and purified from the hydrolyzates of pig’s spleen, but now can be obtained by chemical synthesis, its chemical name is L-tyrosine-L-serine-L-leucine. Tyroserleutide is an active, low-molecular-weight polypeptide, comprised of three amino acids, that has shown antitumor effects on human hepatocarcinoma BEL-7402 in vitro and in vivo. Tyroserleutide has various advantages over the other bioactive peptides such as its low molecular weight, simple construction, nonimmunogenicity, specificity, few side effects, and ease of synthesis. Tyroserleutide is in Phase-III clinical trials for the treatment of liver cancer.
